Skip to main content

Table 2 COVID-19 symptoms during the previous four weeks at the time of the serosurvey

From: Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival

  Seronegative IgM/IgG (n = 3075) Seropositive IgM/IgG (n = 193) P
Asymptomatic, n (%) 2627 (85.4) 114 (59.1)  < 0.001
Symptomatic, n (%) 448 (14.6) 79 (40.9)  < 0.001
Self-reported symptoms    
Cough, n (%) 119 (3.9) 47 (24.4)  < 0.001
Sore throat, n (%) 202 (6.6) 33 (17.1)  < 0.001
Nasal discharge, n (%) 85 (2.8) 15 (7.8) 0.001
Headache, n (%) 173 (5.6) 32 (16.6)  < 0.001
Anosmia, n (%) 63 (2.0) 40 (20.7)  < 0.001
Muscle/body aches, n (%) 98 (3.2) 31 (16.1)  < 0.001
Diarrhea, n (%) 92 (3.0) 23 (11.9)  < 0.001
Fever, n (%) 62 (2.0) 29 (15.0)  < 0.001
Shortness of breath, n (%) 40 (1.3) 21 (10.9)  < 0.001
Contact with confirmed case, n (%) 416 (13.5) 39 (20.2) 0.013
  1. COVID-19 Coronavirus disease 2019, IgG Type G immunoglobulin, IgM Type M immunoglobulin